Variantes histológicas del carcinoma urotelial con implicaciones diagnósticas, pronósticas y terapéuticas

Picazo, M.L.; Regojo, R.Ma; González‐Peramato, Pilar

doi:10.1016/s0210-4806(07)73762-2

Cited by 8 publications

(1 citation statement)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 Early cystectomy is recommended by most authorities. 9 In the current study, 6 patients with the nested variant did rather well. After a median follow-up of 75 months, 2 patients were found to have tumor progression, of which one patient underwent radical cystectomy and other underwent chemo radiation but none died from UC.…”

Section: Discussionsupporting

confidence: 41%

Is radical cystectomy mandatory in every patient with variant histology of bladder cancer

et al. 2011

View full text Add to dashboard Cite

Urothelial carcinomas have an established propensity for divergent differentiation. Most of these variant tumors are muscle invasive but not all. The response of non muscle invasive variant tumors to intravesical immunotherapy with BCG is not established in the literature, and is reported here. Between June 1995 and December 2007, 760 patients (mean age of 67.5 years) underwent transurethral resection of first time bladder tumors in our institution. Histologically variant tumors were found in 79 patients (10.4%). Of these 57 patients (72%) of them had muscle-invasive disease or extensive non-muscle invasive tumors and remaining 22 patients (28%) were treated with BCG immunotherapy. These included 7 patients with squamous differentiation, 4 with glandular, 6 with nested, 4 with micropapillary and 1 patient with sarcomatoid variant. The response of these patients to immunotherapy was compared with that of 144 patients having high-grade conventional urothelial carcinomas. Median follow-up was 46 months. The 2 and 5-year progression (muscle-invasion) free survival rates were 92% and 84.24% for patients with conventional carcinoma compared to 81.06% and 63.16% for patients with variant disease (P=0.02). The 2 and 5-year disease specific survival rates were 97% and 91.43% for patients with conventional carcinoma compared to 94.74 % and 82% for patients with variant disease (P=0.33). 5 patients (22.7%) of variant group and 13 patients (9.03%) of conventional group underwent cystectomy during follow-up (P=0.068).Patients with non-muscle invasive variants of bladder cancers can be managed with intravesical immunotherapy if tumor is not bulky (>4 cm). Although progression to muscle invasive disease is more common than in conventional group and occurs in about 40% of the patients, life expectancy is similar to patients with conventional high-grade urothelial carcinomas provided that follow-up is meticulous.

show abstract

Section: Discussionsupporting

confidence: 41%